

Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by  
Eliminating Tumor-Resident Intracellular Bacteria

*Xiaoxu Kang, Fanqiang Bu, Wenli Feng, Fang Liu, Xuankun Yang, Haofei Li, Yingjie Yu,  
Guofeng Li, Haihua Xiao, and Xing Wang\**

X. Kang, F. Bu, W. Feng, X. Yang, H. Li, Y. Yu, G. Li, and X. Wang,

State Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory of Biomedical  
Materials, Beijing University of Chemical Technology, Beijing 100029

E-mail: wangxing@mail.buct.edu.cn

F. Liu,

Department of Oncology of Integrative Chinese and Western Medicine, China-Japan  
Friendship Hospital, Beijing, 100029, P. R. China

H. Xiao,

Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and  
Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.

This article has been accepted for publication and undergone full peer review but has not been  
through the copyediting, typesetting, pagination and proofreading process, which may lead to  
differences between this version and the [Version of Record](#). Please cite this article as [doi:  
10.1002/adma.202206765](#).

This article is protected by copyright. All rights reserved.

**Keywords:**

dual-cascade responsive, tumor-resident intracellular bacteria, bacteria-mediated drug inactivation, precise drug delivery, pancreatic cancer

**Abstract**

The limited drug penetration and robust bacteria-mediated drug inactivation in pancreatic cancer result in the failure of chemotherapy. To fight against these issues, a dual-cascade responsive nanoparticle (sNP@G/IR) that can sequentially trigger deep penetration, killing of intratumor bacteria, and controlled release of chemo-drug, is reported. sNP@G/IR consists of a hyaluronic acid (HA) shell and glutathione (GSH) responsive polymer-core (NP@G/IR) that encapsulates gemcitabine (Gem) and photothermal agent (IR1048). The polymer core, as an antibiotic alternative, is tailored to exert the optimal antibacterial activity and selectivity. sNP@G/IR actively homes in tumor due to CD44 targeting of the HA shell, which is subsequently degraded by the hyaluronidase in extracellular matrix. The resultant NP@G/IR in a decreased size and reversed charge facilitates deep tumor penetration. After cellular endocytosis, the exposed guanidine on NP@G/IR kills intracellular bacteria through disrupting cell membranes. Intracellular GSH further triggers the controlled release of cargos. Thus, the protected Gem eventually induces cell apoptosis. Under laser irradiation, the hyperthermia of IR1048 helps further elimination of tumors and bacteria. Moreover, sNP@G/IR activates immune response, thereby reinforcing anticancer capacity. Therefore, this dual-cascade responsive sNP@G/IR eliminates tumor-resident intracellular bacteria and augments drug delivery efficacy, providing a new avenue for improving cancer therapy.

This article is protected by copyright. All rights reserved.

## 1. Introduction

Pancreatic cancer is a highly fatal malignancy with a five-year survival rate that remains under 10% after decades of efforts.<sup>[1]</sup> The main drawbacks of current pancreatic cancer chemotherapy include: i) numerous tumor biological barriers prevent drug penetration and efficient cellular internalization, leading to poor delivery efficiency;<sup>[2]</sup> ii) various inactivation processes of drugs result in chemotherapeutic inefficiency and resistance.<sup>[3]</sup> Therefore, it is essential to develop a novel antitumor strategy that can not only augment drug transportation/penetration but also prevent drug inactivation to improve the treatment of pancreatic cancer.


To overcome tumor biological barriers, numerous engineered nanoparticles have been developed.<sup>[4]</sup> The use of responsive nano-delivery systems, which can modulate their physical properties (*e.g.*, undergo size changes and charge reversal) in response to exogenous stimuli (*e.g.*, light, irradiation) or endogenous stimuli (*e.g.*, enzymes, pH, redox state), is considered an ideal strategy for deep tumor penetration.<sup>[5]</sup> However, inaccurate and uncontrolled release of a drug usually results in poor treatment efficacy.<sup>[4,6]</sup> As such, it is highly desirable to develop a cascade-responsive nano-delivery system that can sequentially enhance tumor penetration and precisely control intracellular drug release to improve delivery efficiency.

Drug inactivation is another key parameter that determines the fate of a certain therapy.<sup>[7]</sup> Tumor-resident bacteria were reported to be responsible for drug inactivation. Bacterial enzymes can metabolize drugs to inactive forms, finally resulting in drug resistance.<sup>[8]</sup> Notably, the bacteria are present in the tumors of most patients with pancreatic cancer.<sup>[8,9]</sup> To prevent drug inactivation specially by bacteria, delivery of anticancer drugs accompanied by

a certain antibiotic can help kill bacteria and thereby overcome bacteria-induced drug resistance.<sup>[10]</sup> While the simultaneous release strategy cannot completely block the degradation of drugs by bacteria due to hysteresis of the antibiotic bactericidal process. Furthermore, recent studies highlighted that the intratumoral bacteria are mostly intracellular.<sup>[11]</sup> The membrane barrier and harsh environment of host cells could also decrease intracellular accumulations of antibiotics and impair their efficacy.<sup>[12]</sup> Besides, long-term use of antibiotics is prone to inducing bacterial resistance.<sup>[13]</sup> As an alternative therapy, antibacterial polymers have shown the ability to overcome antibiotic resistance and treat recurring infections by a fast disruption of membrane.<sup>[14]</sup> Thus, using an antibacterial polymer to deliver anticancer drugs, enabling rapidly bactericidal action before drug release, could offer an optimal option to overcome bacteria-mediated drug inactivation.

Gemcitabine (Gem), a cytidine nucleoside analog and the gold standard treatment drug for pancreatic cancer in clinics,<sup>[15]</sup> is exactly such a drug that has difficulty in penetrating the dense tumor tissues and can be metabolized by bacteria in tumors.<sup>[9]</sup> Herein, we proposed a dual-cascade responsive nanoparticle with a so-called “offensive-defensive” maneuver to enhance pancreatic cancer therapy (**Scheme 1**), which can eliminate tumor-resident intracellular bacteria and realize precise drug delivery. An amphiphilic GSH-responsive polymer (SGP) with optimal antibacterial activity and selectivity was first used to load Gem and IR1048 to form a core nanoparticle (NP@G/IR, as shown in **Scheme 1A**). It was further coated with an enzyme-responsive hyaluronic acid (HA) to obtain the dual-cascade responsive nanoparticle (sNP@G/IR). With this subtle assembly (**Scheme 1B**), i) sNP@G/IR preferentially accumulated in the tumor site due to CD44 targeting of the HA shell, which could be subsequently degraded by hyaluronidase (HAase) in the extracellular matrix (ECM). ii) The released NP@G/IR in a decreased size and reversed charge facilitated deep tumor

penetration. In this process, NP@G/IR killed encountered bacteria. Then, iii) positively charged NP@G/IR rapidly entered tumor cells. Their guanidine groups further killed the intracellular bacteria through disrupting the bacterial membrane. Besides, intracellular GSH triggered disulfides breaking for controlled release of Gem and IR1048. Gem could thus be protected maximally from bacterial metabolism and successfully kill cancer cells. Moreover, the topical hyperthermia generated by IR1048 under laser irradiation improved the anticancer effect and bacterial elimination. Thereafter, iv) this treatment also modulated the innate immune responses of tumors by promoting the production of cytotoxic T cells, so as to reinforce the anticancer effect. In this way, bacteria in the tumor were eliminated and the Gem was protected synergistically, performing the exciting “offensive-defensive” maneuver. Therefore, the intelligent sNP@G/IR could greatly improve the therapeutic effect on pancreatic cancer.



**Scheme 1.** (A) Preparation process of the dual-cascade responsive sNP@G/IR with core-shell structure. (B) sNP@G/IR suppresses bacteria-colonized tumor growth by eliminating tumor-resident intracellular bacteria and precise drug delivery. The process is divided into 4 steps: i) HAase in ECM promotes shell detachment and exposure of core nanoparticles (NP@G/IR); ii) the bare NP@G/IR with decreased particle size and reversed charge achieves deep tumor penetration and extracellular bacterial killing; iii) after rapid endocytosis, NP@G/IR facilitates the elimination of intracellular bacteria and the controlled release of drugs; iv) and immune activation by triggering CD8<sup>+</sup> T cells production.

## 2. Results and Discussions

### 2.1. Synthesis and Characterization of Polymers

The synthesis route of SGP is shown in **Scheme S1**. First, a disulfide containing polymer, (poly(CHTA-*co*-HD)-PEG) (donated as SP), with pair-wised pendant carboxyl groups was synthesized.<sup>[16]</sup> According to the <sup>1</sup>H NMR and GPC, the molecular weight ( $M_w$ ) of SP was  $\approx$  18000 g/mol (**Figure S1** and **S2**). Polyhexamethyleneguanidine hydrochloride (PHMG), a commercially available guanidine-based antibacterial agent,<sup>[17]</sup> was introduced to the SP chain to synthesize SGP by an amide condensation reaction. PHMG endows SGP with high efficiency and long-term bactericidal properties.<sup>[18]</sup> However, we found that the increased amount of PHMG would result in high cytotoxicity. To balance the antibacterial activity and biocompatibility, a series of SGPs with different ratios of SP and PHMG (2:1, 5:1 and 10:1) were prepared, denoting as SGP<sub>1</sub>, SGP<sub>2</sub> and SGP<sub>3</sub>, respectively. <sup>1</sup>H NMR results showed that the grafted PHMG units in SGP<sub>1</sub>, SGP<sub>2</sub> and SGP<sub>3</sub> were calculated to be 13, 7, and 4, respectively (**Figure S3** and **Table S1**). Such a modulation offered an opportunity to balance the antibacterial activity and selectivity of SGPs.

The antibacterial activity of SGPs was determined through the minimum inhibitory concentration (MIC) against the model bacterium, *E. Coli* Nissle 1917 (EcN). EcN has been reported to metabolize Gem to an inactive form.<sup>[9]</sup> SGPs displayed PHMG-ratio dependent activity against EcN. SGP<sub>1</sub> and SGP<sub>2</sub> showed better antibacterial activity with MICs of 62.5  $\mu$ g/mL and 250  $\mu$ g/mL, respectively. While the MIC of SGP<sub>3</sub> was found over 250  $\mu$ g/mL. To investigate the membrane-disrupting toxicity of SGPs on mammalian cells, their ability to lyse red blood cells was examined.<sup>[19]</sup> The hemolysis of SGPs was determined by HC<sub>10</sub>, *i.e.*, the concentration of polymers to cause 10% hemolysis. The HC<sub>10</sub> of SGPs were 156  $\mu$ g/mL,

5000  $\mu\text{g/mL}$  and  $>5000 \mu\text{g/mL}$ , in above sequence. It showed the increased PHMG units of SGPs enhanced the lysis of RBCs. The selectivity index (SI) was further calculated by  $\text{HC}_{10}/\text{MIC}$ , which could indicate the cell-type selectivity of polymers.<sup>[14c,20]</sup> Among them,  $\text{SGP}_2$  exhibited the best SI value of 20 (**Table S1**), suggesting  $\text{SGP}_2$  was an ideal vehicle to balance antibacterial activity and selectivity. To further confirm this, the cytotoxicity of  $\text{SGP}_2$  on mammalian cells, including mouse epithelioid fibroblasts L929 cells and mouse pancreatic cancer cells Pan02, was examined by methyl thiazolyl tetrazolium (MTT) assay (**Figure S4**). The cell viabilities of these two cell lines were both above 80% when  $\text{SGP}_2$  at 250  $\mu\text{g/mL}$  ( $1 \times \text{MIC}$ ), indicating  $\text{SGP}_2$  has good biocompatibility and was suitable to use as a drug vehicle.<sup>[21]</sup>

## 2.2. Assembly and Characterizations of Nanoparticles

To prepare nanoparticles (NPs),  $\text{SGP}_2$  was used to load either Gem or IR1048, as well as to co-load both Gem and IR1048 (**Table S2**). The obtained NPs were called as NP@G, NP@IR, and NP@G/IR, respectively. As a control,  $\text{SGP}_2$  was allowed to self-assemble into blank NPs without Gem and IR1048 (denoted as  $\text{NP}_0$ ). The highest drug loading content (DLC) of Gem and IR 1048 in NP@G/IR reached 19.9% and 9.7%, respectively (**Table S3**). Subsequently, HA was coated on above-mentioned NPs to form the final NPs, *i.e.*, sNP@G, sNP@IR, sNP@G/IR, and sNP<sub>0</sub> (**Table S2**). The spherical morphologies of NP@G/IR and sNP@G/IR with uniform sizes were observed by TEM (**Figure 1A, B**). sNP@G/IR exhibited a distinct core-shell structure. The DLS results demonstrated that the size of NP@G/IR increased from 64.1 nm to 152.3 nm after HA coating (sNP@G/IR), while the zeta potential decreased from +11.7 mV to -13.0 mV (**Figure 1D, E**, and **Figure S5**). In the presence of HAase, the HA


shell in sNP@G/IR was degraded to expose NP@G/IR (**Figure 2C**), resulting in a size decrease to 73.0 nm, and a zeta potential shift to +0.1 mV (**Figure 1D, E**). Afterwards, the size stability of NP@G/IR and sNP@G/IR was tested in various culture media (**Figure S6**). NP@G/IR and sNP@G/IR maintained relatively uniform hydrodynamic sizes in PBS, water, 10% FBS, and LB medium for 5 days, suggesting that they were stable and suitable for anticancer or antibacterial applications.

GSH can trigger the breakage of disulfide bonds in SGP.<sup>[22]</sup> In order to test the GSH-responsive behavior of SGP<sub>2</sub>, a validated assay *via* a 1,2-benzenedicarboxaldehyde (OPA) derivative was performed by monitoring the breakage of the disulfide units in the polymer chain (**Scheme S2**).<sup>[23]</sup> The half-lives of GSH incubated with 2-hydroxyethyl disulfide and SGP<sub>2</sub> were 3.0 h and 1.7 h, respectively (**Figure S7A-D**). Furthermore, the GSH-responsiveness of SGP<sub>2</sub> was confirmed by GPC. After incubation with 10 mM GSH for 24 h, the  $M_w$  of SGP<sub>2</sub> decreased from 23099 g/mol to 6295 g/mol. This implied that SGP has been degraded to methoxyl-polyethylene glycol (mPEG<sub>5K</sub>) and other small fragments (**Figure S7E**).

sNP@G/IR is responsive to both HAase and GSH. To demonstrate whether its dual responsiveness is in a cascade manner, we explored the particle size and polydispersity index (PDI) changes of sNP@G/IR in the mimicked tumor microenvironment (**Figure 1F** and **Figure S8**). In the HAase-free environment, sNP@G/IR was stable even in the presence of GSH. In contrast, HAase incubation could lead to a size decrease of approximately 60 nm in sNP@G/IR at 4 h. Prolonging incubation time, the obtained NP@G/IR was stable. But in the presence of GSH, NP@G/IR would collapse completely owing to the exposure and breakage of disulfide bonds, thus resulting in a cascade-responsiveness on HAase-GSH.

Gem release profiles were evaluated in different solutions (**Figure 1G, H**). At pH 7.4, pH 5.0 and 10 mM of GSH, the release rates of Gem from sNP@G/IR were 26.34%, 29.90%, and 34.55% after 48 h respectively. After detaching the HA shell of sNP@G/IR by the addition of HAase, the percentage of Gem released from NP@G/IR did not show notable changes at pH 7.4. In contrast, Gem was released very rapidly at pH 5.0 or in the presence of GSH, which was up to 66.6% and 93.7%, respectively. Accordingly, we can infer that sNP@G/IR may have better performance in blood circulation while avoiding the immature leakage of anticancer drugs with a high chance of successfully delivering anticancer drugs to tumor sites and cellular loci.

The photothermal properties of sNP@G/IR were then examined. Because of the loaded IR1048, the NPs showed an absorption peak at 1051 nm in the UV spectra (**Figure S9A**).<sup>[24]</sup> After irradiating with 1064 nm light at 1.0 W/cm<sup>2</sup> for 10 min, the solution temperature of sNP@G/IR increased by 15.4 °C and 41.8 °C at 2.5 µg/mL and 40 µg/mL of IR1048 respectively (**Figure 1I**, and **Figure S9B**). Moreover, sNP@G/IR exhibited good photothermal stability, and the thermal effect of the sNP@G/IR solution did not diminish after four times of laser on/off cycles (**Figure S9C**). These studies confirmed the good photothermal therapeutic ability of sNP@G/IR.



**Figure 1.** *In vitro* characterizations of sNP@G/IR. TEM images of (A) NP@G/IR, (B) sNP@G/IR and (C) sNP@G/IR incubated with HAase (110 IU/mL). (D) Particle size and (E) zeta potential of NP@G/IR, sNP@G/IR, and sNP@G/IR incubated with HAase,  $n = 3$ . (F) Particle size variation of sNP@G/IR in various buffer solutions at pH 6.5. i. HAase; ii. 10 mM GSH; iii. HAase and 10 mM GSH,  $n = 3$ . Gem release profiles of sNP@G/IR in different conditions (G) without HAase and (H) with HAase,  $n = 3$ . (I) Temperature variation curves of

This article is protected by copyright. All rights reserved.


sNP@G/IR solutions in water at various IR1048 concentrations after irradiation by a 1064 nm laser at 1.0 W/cm<sup>2</sup> for 10 min.

### 2.3. *In Vitro* Antibacterial Activity

To verify the antibacterial activity of sNP@IR, various formulations (*i.e.*, PBS, NP<sub>0</sub>, sNP, NP@IR, sNP@IR) were inoculated with EcN suspensions in LB medium, and the OD<sub>600</sub> was measured at specific times. After sNP<sub>0</sub> treatment, the starting point of exponential growth period was postponed from 4 h to 12 h, while in the sNP@IR+L group, the replication of bacteria was completely inhibited within 24 h (**Figure 2A**). Furthermore, the quantitative antibacterial efficiency was evaluated by a colony count method. There was a 3-Log<sub>10</sub> CFU reduction in the number of bacterial colonies after being treated with sNP<sub>0</sub> for 8 h, and bacteria treated with sNP@IR+L were all killed (**Figure 2B, C**). These results suggested that guanidine conferred good antibacterial activity of sNP@IR, and the photothermal effect triggered by IR1048 laser irradiation provided a powerful boost for complete bacterial eradication.

Furthermore, the antibacterial activity of sNP@IR was visualized using a LIVE/DEAD™ Bacterial Viability Kit by confocal laser scanning microscope (CLSM) (**Figure S10**). Most of the bacteria exhibited green fluorescence (live) when treated with PBS, and an increased red fluorescence (dead) was found in the bacteria treated with sNP<sub>0</sub>. Following sNP@G/IR treatment upon laser irradiation, almost all bacteria exhibited red fluorescence (dead), which was consistent with the results of the growth curves and colony counts.

To figure out the intrinsic mechanism, the interaction between NP<sub>0</sub> and EcN was explored. SGP<sub>2</sub> loaded with Rhodamine B (RhB) assembled into NPs (denoted as NP@RhB) in DMSO/water. As shown in **Figure 2D**, NP@RhB exhibited red fluorescence and was mostly co-located with the green EcN. The fluorescence (FL) intensity profiles showed a high overlap of red and green fluorescence, indicating that NP@RhB could actively bind to the bacteria (**Figure 2E**). Further, 3,3'-dipropylthiadicarbocyanine iodide (DiSC<sub>35</sub>) dye, which can probe changes in plasma membrane potential, was applied to evaluate the bacterial plasma membrane depolarization ability of the NP<sub>0</sub>.<sup>[25]</sup> The FL intensity of EcN obviously increased after treating with NP<sub>0</sub> for 30 min, and the increase was positively correlated with the concentration of NP<sub>0</sub> (**Figure 2F**). These results suggested that NP<sub>0</sub> would depolarize the membrane after binding the bacterial membrane. Subsequently, we observed the morphology of bacteria with different treatments (**Figure 2G**). SEM images showed that the bacteria in the control PBS groups were normal in shape and maintained clear borders as well as membrane integrity. However, there was a severe collapse of the bacterial cell membrane. The cell wall fragmentation and irregularly shaped pores could be seen clearly in the bacteria treated with various NPs. These suggested that sNP@IR exerted antibacterial properties by disrupting bacterial cell membranes and cell walls, which were conferred by guanidine groups and photothermal effect.<sup>[18b,26]</sup>



**Figure 2.** *In vitro* antibacterial activity of sNP@IR. (A) Growth curves of EcN with various drugs. The concentrations of SGP<sub>2</sub> and IR1048 were set at 100 μg/mL and 7 μg/mL respectively, n = 3. (B) Colony plate images and (C) the colony-forming units (CFUs) statistics of EcN treated with various drugs at 8 h in LB medium, n = 3. (D) Confocal images of GFP-labeled EcN treated with NP@RhB for 30 min. (E) Co-localization FL intensity profiles of GFP-labeled EcN and NP@RhB. (F) The membrane depolarization of EcN treated

with NP<sub>0</sub>. (G) SEM images of EcN treated with different drugs. The yellow arrows indicate the shape damage to bacterial cells. \*\*\*\*,  $p < 0.0001$ , ns,  $p > 0.05$ , respectively.

#### 2.4. *In vitro* intracellular anticancer activity and antibacterial activity

In order to explore the intracellular mechanism of sNP@G/IR, CLSM and flow cytometry were performed respectively to visualize and quantify the cellular uptake of sNP@G/IR.<sup>[28]</sup> Firstly, both NP<sub>0</sub> and sNP<sub>0</sub> encapsulating RhB were prepared and denoted as NP@RhB and sNP@RhB, respectively. As the co-incubation time of Pan02 cells increased, the intracellular red FL intensity increased quickly in the sNP@RhB group, suggesting rapid internalization of sNP@RhB (**Figure S11**). Meanwhile, in the NP@RhB group, the similar phenomena could be seen (**Figure 3A**). Quantitative analysis by flow cytometry further confirmed above uptake behaviors (**Figure 3B**, and **Figure S12**), although these two NPs had different surface functional groups.

Since sNP@RhB was designed with HA shell to shield positive charge of NP@RhB while assembling targeted HA molecules on its surface, the endocytosis pathway of sNP@RhB should be precise recognition of HA pendants, rather than the general charge interaction between NP@RhB and cells.<sup>[27]</sup> To validate the recognition process, a competitive inhibition assay was performed (**Figure 3A**, **B**, and **Figure S13**). Free HA molecules were employed here for the pre-incubation for 2 h. After that, both sNP@RhB and NP@RhB were added to the cultures. Significantly, the red FL intensity in sNP@RhB-treated cells was sharply decreased (\*\*\*\*,  $p = 0.0000008$ ), while that in NP@RhB-treated cells was still strong. Depending on literatures report,<sup>[28]</sup> the cellular uptake of sNP@RhB should be a CD44 receptor-mediated endocytosis pathway. Thus, HA coating upgraded the common


electrostatic interaction between guanidine groups on NP@RhB and cell membranes that could lead to a rapid internalization of most NPs.

Subsequently, the lysosomal escape behavior of sNP@RhB was examined. sNP<sub>0</sub> was first labeled with fluorescein isothiocyanate (FITC) that was denoted as sNP@FITC (green). The lysosomes of Pan02 cells were stained in red fluorescence by a Lyso-Tracker Red dye. After 3 h co-incubation of sNP@FITC, the green and red fluorescence in Pan02 cells mostly overlapped (**Figure 3C**, **Figure S13A**). After refreshing the culture medium (to remove NPs) and culturing additional 1 h and 3 h, overlap of the green and red fluorescence decreased with time prolonging. The co-localization ratio between sNP@FITC and lysosomes was calculated beyond 66% before refreshing the medium (**Figure 3D**, **Figure S13B**), while decreased to lower than 30% after additional 3 h culture (\*\*\*,  $p = 0.0001$ ). In addition, when the cells were pre-treated with HA, the co-localization ratio was only 49% as beginning and decreased to lower than 18% according to the above test points (\*\*\*\*,  $p = 0.0000007$ ). These phenomena not only demonstrated the specific targeting action, but also revalidated the lysosomal escape of sNP. This behavior can be attributed to the degradation of the HA shell in lysosome, leading to guanidine exposure of the sNP and facilitating the transport of the resulted NP from lysosome to cytoplasm.<sup>[29]</sup> The above maneuvers were essential for exerting intracellular antibacterial and anticancer activities.

Next, cytotoxicity of sNP@G/IR was assessed by an MTT assay. Due to the combined potency of Gem and hyperthermia, more than 85% of cells were killed according to a relatively cell viability of 14.18% in sNP@G/IR+L group by loading 1  $\mu\text{g/mL}$  Gem and 3.75  $\mu\text{g/mL}$  IR1048 (**Figure 3E**). When sNP@G was used without laser irradiation, 52% of cells were killed due to the drug release of Gem; while when utilizing sNP@IR, most of the cells

survived without laser treatment but only 60% of live cells were left under laser condition (**Figure S14**). Obviously, Gem and hyperthermia contributed comparable amounts of cytotoxicity. In-depth analysis revealed that sNP@G/IR+L induced an apoptosis rate of 90.68% (**Figure 3F, Figure S15**), while in the sequence of Gem, sNP@G, and sNP@IR+L, the rates were 23.29%, 38.75% and 58.02%, respectively. This outcome was consistent with the results of cytotoxicity.

The bactericidal ability of sNP@IR against intracellular bacteria (EcN) was further tested based on abundant intracellular bacteria in tumors.<sup>[12]</sup> Pan02 cells infected with EcN (multiplicity of infection = 10, see SI for the details) were treated with various NPs and then were lysed by 0.1% Triton X-100 for CFUs counting (**Figure 3G**). For the employed sNP@IR, the concentrations of SGP<sub>2</sub> carrier and IR1048 were 256 µg/mL and 17.9 µg/mL. Hence, the intracellular EcN was significantly suppressed when treated by sNP<sub>0</sub> for 24 h (5-Log<sub>10</sub> CFU reduction in **Figure 3H**, \*\*\*\*,  $p = 0.00001$ ), which was contributed to the excellent membrane penetration ability and efficient bactericidal activity. Besides, NP<sub>0</sub> displayed the same bactericidal activity due to similar cellular uptake (**Figure 3A**). After laser exposure, both NP@IR and sNP@IR could completely kill intracellular EcN (\*\*\*\*,  $p = 0.00001$ ), indicating the superior efficacy to eliminate intracellular bacteria by the combination of guanidine and photothermal treatment.



**Figure 3. The intracellular behavior of sNP@G/IR *in vitro*.** (A) CLSM images and (B) fluorescence profiles of Pan02 cells pretreated with or without HA and then incubated with NP@RhB and sNP@RhB for 3 h. (C) CLSM images of the co-localization sNP@FITC and lysosomes in Pan02 cells pretreated with or without HA. After 3 h of incubation with sNP@FITC, the NPs were removed and the cells were incubated for an additional 1 h or 3 h for CLSM observation. Blue fluorescence comes from cell nucleus, red fluorescence comes from lysosomes, and green fluorescence comes from sNP@FITC, respectively. (D) The

This article is protected by copyright. All rights reserved.

corresponding overlap efficiency between sNP@ FITC and lysosomes, which was analyzed by software *Image J*. Pearson's correlation coefficient is denoted as PCC,  $n = 5$ . (E) Relative cell viability of Pan02 cells following various treatments,  $n = 3$ . (F) Cell apoptosis rate of Pan02 cells treated with different formulations, as determined by flow cytometry,  $n = 3$ . (G) Photos and (H) CFUs of intracellular EcN with different treatments. The corresponding concentrations of SGP<sub>2</sub> and IR1048 was 256  $\mu\text{g/mL}$  and 17.9  $\mu\text{g/mL}$ , respectively. \*\*\*\*  $p < 0.0001$ , \*\*\*  $p < 0.001$ , \*\*  $p < 0.01$ , and \*  $p < 0.05$ , respectively.

sNP@IR exhibited excellent ability to eliminate intracellular bacteria, which inspired us to evaluate the performance of sNP@G/IR to protect Gem when cocultured with bacteria. High-performance liquid chromatography (HPLC) was performed to determine the concentration of Gem under various conditions. The retention time of Gem in RPMI 1640 medium could be referred at 8.492 min (**Figure S16**, blue curve). But when cocultured with EcN, no intact Gem could be found, confirming the bacteria-mediated inactivation (**Figure S16**, red curve). Excitingly, the conservation rate of Gem was found to be approximately 83% in the coculture suspensions of sNP@G/IR and EcN after 1064 nm laser irradiating for 10 min at 1.0  $\text{W/cm}^2$  (**Figure S16**, green curve). This result suggested that Gem was successfully protected by sNP@G/IR from bacteria-mediated inactivation.

Furthermore, comprehensive assessment for killing cancer cells with infected bacteria was carried out. The bacteria-cell coculture system was achieved by adding bacterial suspensions to adherent Pan02 cells,<sup>[11]</sup> in which both extra- and intra-cellular bacteria were existed. After treatments with above NPs, the bacterial colonies were plated on LB agar, and the cell survival rates were evaluated by a live/dead staining kit. To validate this model, free Gem

herein did not perform any efficiency with a live cell ratio of 90.62%. When treated with sNP@G, a live cell ratio of 64.48% was recorded at the same concentration of Gem (**Figure S17**), meanwhile resulting in 1.6-Log<sub>10</sub> CFU reduction of EcN (\*\*\*\*,  $p = 0.00001$ , **Figure S18**). After introducing photothermal treatment, sNP@G/IR killed EcN by 99.98% (3.7-Log<sub>10</sub> CFU reduction, \*\*\*\*,  $p = 0.00001$ ), and Pan02 cells by 98.03% (red in live/dead confocal images). These results demonstrated the hypothesis that the proposed sNP@G/IR could exert the effectiveness of Gem by a sequential process of bactericidal and drug-release, and potentially would display superior therapeutic effects on cancer cells with commensal bacteria.


## 2.5. Evaluation of Deep Tumor Penetration, Targeting and Photothermal Performances

*In vitro* three-dimensional (3D) multicellular tumor spheroids (MTSs) mimicking Pan02 tumor tissues were adopted, to evaluate the penetration of sNP@G/IR. The strong fluorescence in Pan02 MTSs incubated with sNP@RhB was observed in CLSM images at the cross-section of 32  $\mu\text{m}$  (**Figure 4A**). Whereas with the increase of depth from 32  $\mu\text{m}$  to 48  $\mu\text{m}$ , the fluorescence gradually weakened. When the Pan02 MTSs were pre-treated with HAase for 2 h,<sup>[5c]</sup> a stronger FL intensity was detected (**Figure 4A, B**), even at 48  $\mu\text{m}$  (**Figure S19**). These results demonstrated that the HA shell degradation of sNP@RhB could enhance deep penetration because of the decreased particle size and increased zeta potential.

Subsequently, the *in vivo* biodistribution of sNP@G/IR was assessed in Pan02 tumor-bearing C57BL/6 mice by an *in vivo* imaging system (IVIS). Cy7.5 was adopted to label NP<sub>0</sub> and sNP<sub>0</sub> which were denoted as NP@Cy7.5 and sNP@Cy7.5, respectively. The following *in vivo* imaging showed the accumulation of NP@Cy7.5 and sNP@Cy7.5 in the

tumor region increased gradually and peaked at 9 h after drug intravenous (i.v.) injection (**Figure 4C, D**). Clearly, the HA coating rapidly improved the accumulation just from 3 h. Tumors in the sNP@Cy7.5-treated mice had stronger FL intensity than those in the NP@Cy7.5 treatment group (\*,  $p < 0.05$ ), demonstrating the good targeting capability of sNP@Cy7.5. In addition, the distribution of fluorescence in tumors and major organs at 9 h was tracked (**Figure S20**). Quantitative FL intensity of tumor-to-normal tissues in the mice injected with sNP@Cy 7.5 was approximately 3 times that in the NP@Cy7.5 injected group (\*,  $p = 0.01$ ) (**Figure 4E**), proving a better tumor targeting and penetration of sNP@G/IR *in vivo*.

Furthermore, the photothermal performance *in vivo* of sNP@G/IR was examined (**Figure 4F**). Compared to the PBS-treated mice, an obvious temperature increase was recorded in the tumors of mice treated with NP@G/IR and sNP@G/IR, respectively. Notably, the temperature change in tumors of mice treated with sNP@G/IR ( $\Delta T$  12.6 °C) was also higher than that in the NP@G/IR treatment group ( $\Delta T$  10 °C), which agreed with the results from IVIS.



**Figure 4.** *In vitro* permeability as well as *in vivo* targeting ability and photothermal performance of sNP@G/IR. (A) CLSM images of Pan02 cells treated with sNP@RhB and HAase + sNP@RhB for 3 h. (B) The variance in fluorescence signal intensity along the yellow lines from the Pan02 MTSs. (C) The tumor targeting study of NP@Cy7.5 and

This article is protected by copyright. All rights reserved.

sNP@Cy7.5 in Pan02 tumor-bearing mice. (D) The corresponding FL intensity of the tumor site at different time points,  $n = 3$ . (E) *Ex vivo* analysis of tumor-to-normal tissues FL intensity ratio at 9 h after i.v. injection of NP@Cy7.5 and sNP@Cy7.5,  $n = 3$ . (F) Temperature variation curves at the tumor sites of Pan02 tumor-bearing mice under 1064 nm laser irradiation with a power of  $1.0 \text{ W/cm}^2$  for 10 min (Gem, 10 mg/kg, IR1048, 3 mg/kg, i.v. injection). \*  $p < 0.05$ .

## 2.6. *In Vivo* Biosafety and Therapeutic Evaluation

To systematically investigate the biosafety profiles, healthy C57BL/6 mice ( $n = 3$ ) were administered with PBS, sNP@G, sNP@IR and sNP@G/IR by i.v. injection. The formulations were subjected to mice once every 2 days for 14 days. The weight of the mice in the treatment groups showed no difference in comparison with that of mice in the PBS group (**Figure S21A**). After 14 days, the blood and major organs (including heart, liver, spleen, lung, and kidney) of mice were collected. The serum biomarkers were all at normal levels compared to the control. Hematoxylin and eosin (H&E) staining of the major organs exhibited normal histomorphology with no obvious pathological abnormalities. Taken together, sNP@G, sNP@IR and sNP@G/IR displayed acceptable biocompatibility (**Figure S21B, C**).

The *in vivo* therapeutic efficacy of sNP@G/IR on bacteria-free Pan02 tumor-bearing mice was first evaluated. The mice were randomly grouped, including PBS, Gem, NP@G, sNP@G, NP@IR+L, sNP@IR+L, NP@G/IR+L, and sNP@G/IR+L, respectively. As shown in **Figure S22A**, the mice were administered with these formulations at day 1, 4, and 7. At 9 h after injection, the tumors of mice in NP@IR+L, sNP@IR+L, NP@G/IR+L, and

sNP@G/IR+L groups were irradiated with a 1064 nm laser under 1.0 W/cm<sup>2</sup> for 10 min. Compared with free Gem (43.4% in tumor inhibition), sNP@G treatment exhibited 1.3 times antitumor activity (56.6% in tumor inhibition) due to a greater accumulation of sNP@G at the tumor site (**Figure S22B-D**). Comparatively, sNP@G/IR+L treatment significantly suppressed tumors with a tumor inhibition rate of 98.7% (\*\*\*\*,  $p = 0.000001$ ), indicating the excellent combined therapeutic efficacy of chemotherapy and photothermal therapy (PTT). Compared with NP@G/IR+L group (93.9% in tumor inhibition), the average tumor weight in sNP@G/IR+L group was obviously decreased (\*\*,  $p = 0.006$ ), which was attributed to the tumor-targeted HA shell (**Figure S22D**). In addition, the body weight of mice after different treatments showed no obvious difference (ns,  $p > 0.05$ ) (**Figure S22E**). Further H&E staining of the tumor sections displayed marked apoptosis as a consequence of chemotherapy and PTT triggered by sNP@G/IR+L treatment (**Figure S22F**).

Encouraged by these results, we further assessed the capability of sNP@G/IR to suppress bacteria-colonized tumors. This tumor model was obtained by injecting EcN bacteria to tumor-bearing mice via i.v. injection.<sup>[9,30]</sup> To verify the successful establishment, FL intensity of tumors and major organs in mice was determined by IVIS after injecting GFP-labeled EcN at different time points. Tumors on days 1, 2, and 3 of bacterial injection all exhibited significantly enhanced FL intensity compared to the uninjected group (\*\*,  $p < 0.01$ ), indicating EcN colonization in the tumor site (**Figure. S23A, B**). Further, the long-term colonization ability of EcN in tumor site was investigated. On day 1, 2, 3, and day 14, tumor tissues isolated from mice were homogenized and plated on LB agar. EcN was confirmed could be stably colonized in tumor tissue with  $\approx 10^8$  CFU/g (**Figure S23C, D**), which is consistent with previous reports.<sup>[31]</sup> Based on these results and in-depth understanding,<sup>[11]</sup> intracellular bacteria in tumor cells were further quantified. Tumor cells were dissociated

from tumor tissues, and extracellular bacteria were subsequently killed by staphylococcal lysozyme. Exactly, more than 50% of the bacteria in tumor tissue are intracellular bacteria (**Figure S22E, F**).


Subsequently, the comprehensive therapeutic efficacy of sNP@G/IR+L against EcN colonized tumors was examined. The mice were randomly divided into 6 groups, including PBS, Gem, sNP@G, sNP@IR+L, NP@G/IR+L, and sNP@G/IR+L. Mice are treated according to the timeline (**Figure 5A**). Similarly, the following conditions, 1064 nm laser at 1.0 W/cm<sup>2</sup> for 10 min, were used in the photothermal treatment groups. On the 7<sup>th</sup> day, after mice were treated twice with different formulations, tumors were extracted from the mice, homogenized and plated on LB agar. Compared with Gem group (7.5 Log<sub>10</sub> CFU) that did not show activity (**Figure 5B, Figure S24**), sNP@G effectively killed intratumor EcN (6.3 Log<sub>10</sub> CFU), with a 1.2-Log<sub>10</sub> CFU decrease owing to the bactericidal guanidine groups. After cooperation with PTT, CFU in sNP@G/IR+L group (3.9 Log<sub>10</sub> CFU) was found significantly lower than that of sNP@G (6.3 Log<sub>10</sub> CFU, \*\*,  $p = 0.004$ ), sNP@IR+L (5.9 Log<sub>10</sub> CFU, \*,  $p = 0.02$ ) and NP@G/IR+L (5.2 Log<sub>10</sub> CFU, \*,  $p = 0.01$ ). sNP@G/IR+L displayed the best bacterial elimination effect. These results manifested that sNP@G/IR was expected to augment the total therapeutic efficacy.

After three times of treatments on day 1, 4, and 7 totally, the relative tumor volume ( $V/V_0$ ) and body weight of mice were then monitored for 14 days. It could be seen that Gem had limited anticancer activity (the  $V/V_0$  was 5.53) due to the bacteria-mediated drug inactivation (to PBS control, ns,  $p > 0.05$ , **Figure 5C**). In contrast, when treating with sNP@G, the  $V/V_0$  was decreased to 2.05 (\*\*,  $p = 0.002$ ) indicating sNP@G improved the treatment effect on tumors by killing the intratumoral bacteria. Notably, the most suppressive ability against

EcN-colonized tumors was shown in sNP@G/IR+L group (the  $V/V_0 = 0.43$ , \*\*\*\*,  $p = 0.00001$ ), which was better than that of NP@G/IR+L group (the  $V/V_0 = 1.20$ , \*,  $p = 0.04$ ). Besides, within 14 days, the body weight of mice subjected to various formalins showed no obvious differences (**Figure S25**).

Furthermore, we examined the survival spans of mice in each treatment group within 60 days. In the groups of PBS, Gem, sNP@G, and sNP@IR+L, all mice died within 52 days. While the median survival time of mice treated with NP@G/IR+L was prolonged to 58 days. In contrast, no mice died within 60 days after sNP@G/IR+L treatment, confirming the distinct efficacy of sNP@G/IR against EcN-colonized tumors (**Figure 5D**).

In addition, the tumor tissues from mice were stained with H&E and TUNEL. The images exhibited that sNP@G/IR+L caused the most serious damage to the tumor tissues and induced the most severe cell apoptosis (**Figure 5E**). Biomarkers (including ALT, ALB, BUN, and CR) in serum from mice were further evaluated and no obvious difference was found compared with the PBS group, indicating the biosafety of above all treatments (**Figure S26**). These results demonstrated that the biocompatible sNP@G/IR combined with chemotherapy and PTT showed the superior therapeutic efficacy on cancer by killing the tumor-resident bacteria.




**5. *In vivo* antitumor efficacy of sNP@G/IR on EcN-colonized subcutaneous Pan02 tumor model.** (A) Timeline of *in vivo* treatment. (B) CFU in tumors of mice receiving different treatments,  $n = 3$ . (C) Relative tumor volume curves of EcN-colonized tumors in mice after different treatments,  $n = 4$ . (D) Survival fractions of mice after different treatments within 60 days. (E) H&E- and TUNEL- stained images of tumor tissues from all groups. \*\*\*\*  $p < 0.0001$ , \*\*\*  $p < 0.001$ , \*\*  $p < 0.01$ , \*  $p < 0.05$ , ns  $p > 0.05$ , respectively.

## 2.7. Immune Evaluation on Bacteria-Colonized Tumor Model

The bacteria death can accelerate the release of lipopolysaccharide (LPS) from gram-negative bacteria, which facilitates the maturation of dendritic cells (DCs).<sup>[11,31]</sup> Moreover, PTT can also activate the immune-response in tumor therapy.<sup>[32]</sup> Thus, we evaluated whether the multifunctional sNP@G/IR+L elicited the immune response in EcN-colonized Pan02 tumors. The rates of mature DCs and CD8<sup>+</sup> T cells in tumors and spleens were detected. The proportion of mature DCs collected from tumors of sNP@G-treated mice reached 29.70%, which was 2.72 times that from the free Gem treatment due to the dual antibacterial and anticancer effects (\*\*,  $p = 0.002$ ). Obviously, the proportion of mature DCs reached 47.30% in the sNP@G/IR+L group, which was 1.59 times that of the sNP@G group (\*\*\*,  $p = 0.0005$ ), confirming that the immune response was significantly enhanced (**Figure 6A**, and **Figure S27**). Furthermore, the intratumor infiltration of CD8<sup>+</sup> T cells were tested to explore the DC-mediated immune response.<sup>[32]</sup> The percentages of CD8<sup>+</sup> T cells in tumor and spleen of control group were 7.72% and 19.26% respectively, while sNP@G/IR+L treatment increased the percentages to 32.72% (\*\*\*,  $p = 0.0002$ ) and 32.85% (\*\*\*\*,  $p = 0.00009$ ) respectively (**Figure 6B, C** and **Figure S28, 29**). Additionally, an immunofluorescence assay was used to check CD8<sup>+</sup> T cells in tumor tissues, which were labeled with red fluorescence. The images displayed that CD8<sup>+</sup> T cells infiltrated tumor most in sNP@G/IR+L group (**Figure 6D, E**), and the red FL intensity was significantly stronger than that of PBS group (\*\*\*,  $p = 0.0007$ ). Proinflammatory cytokines (IL-10, IL-6, TNF- $\alpha$ , INF- $\gamma$ ) in serum were further quantified through an enzyme-linked immunosorbent assay (ELISA). As shown in **Figure 6F-I**, sNP@G/IR+L treatment remarkably decreased the IL-10 (\*,  $p = 0.01$ ) level, but increased the IL-10 (\*,  $p = 0.01$ ),

TNF- $\alpha$  (\*\*,  $p = 0.003$ ) and INF- $\gamma$  (\*,  $p = 0.01$ ) levels. Taken together, the sNP@G/IR activated the tumor immune response, which reinforced anticancer capability.



**Figure 6. Immune activation by sNP@G/IR on a bacteria-colonized tumor model. (A)** Mature DCs in tumors, (B) CD8<sup>+</sup> T cells in tumors and (C) CD8<sup>+</sup> T cells in spleens collected

This article is protected by copyright. All rights reserved.

from bacteria-colonized Pan02 tumor-bearing mice after different treatments,  $n = 3$ . (D) Images of CD8<sup>+</sup> T cell-immunofluorescence staining of tumor tissues from mice after different treatments. (E) The corresponding mean FL intensity (MFI) analysis,  $n = 5$ . (F) IL-10, (G) IL-6, (H) TNF- $\alpha$  and (I) INF- $\gamma$  expression in the serum detected by ELISA kits,  $n = 3$ . \*\*\*\*  $p < 0.0001$ , \*\*\*  $p < 0.001$ , \*\*  $p < 0.01$ , \*  $p < 0.05$ , and ns  $p > 0.05$ , respectively.

### 3. Conclusion

In summary, this study proposed a dual-cascade responsive drug delivery system sNP@G/IR to enhance anticancer efficacy. This sNP@G/IR offered a new case of non-antibiotic therapy, displaying optimal antibacterial activity and selectivity with precise modulating of the guanidine units. The design of dual-cascade responsive endowed sNP@G/IR with multiple functional advantages, including active tumor targeting, deep tumor penetration, increased cellular internalization and controlled drug release. By eliminating tumor-resident intracellular bacteria and augmenting drug delivery efficacy, sNP@G/IR overcame bacteria-mediated Gem inactivation, greatly suppressed bacteria-colonized tumors as well as activated tumor immunity. Overall, this study provides a promising “offensive-defensive” strategy to enhance cancer therapy.

### Supporting Information

Supporting information is available from the Wiley Online Library or from the author.

### Acknowledgements

This work thanks to the National Natural Science Foundation (21574008, 52003161), the National Mega-project for Innovative Drugs (2019ZX09721001-007-002) and the Fundamental Research Funds for the Central Universities (BHYC1705B) of China for the financial support. All animals were treated and cared for in accordance with the National Research Council's Guide for the care and use of laboratory animals and under the supervision and assessment by the SPF Animal Department of Clinical Institute in China-Japan Friendship Hospital (Approval no. zryhy 12-20-08-3). X. W. acknowledges Prof. Lizeng Gao from Institute of Biophysics Chinese Academy of Sciences for gifting the model bacteria (*E. coli* Nissle 1917 and GFP labeled *E. coli* Nissle 1917).

### Author Contributions

X. W. conceived the project. X.W., and X. K. designed the experiments. X. K. performed experimental work and analyzed the data with the help of W. F., G. L., F. B., H. X., and X. W.. In vivo assessments were performed with the help of F. B., W. F., F. L., X. Y., H. L., and Y. Y.. X. K. drafted the manuscript. X. W., H. X., G. L. and Y. Y. edited the manuscript. All authors discussed the results and commented on the manuscript.

### Conflicts of interest

The authors declare no conflict of interest.

## Reference

- [1] a) J. D. Mizrahi, R. Surana, J. W. Valle, R. T. Shroff, *The Lancet* **2020**, 395, 2008; b) E. Riquelme, Y. Zhang, L. Zhang, M. Montiel, M. Zoltan, W. Dong, P. Quesada, I. Sahin, V. Chandra, A. San Lucas, P. Scheet, H. Xu, S. M. Hanash, L. Feng, J. K. Burks, K. A. Do, C. B. Peterson, D. Nejman, C. D. Tzeng, M. P. Kim, C. L. Sears, N. Ajami, J. Petrosino, L. D. Wood, A. Maitra, R. Straussman, M. Katz, J. R. White, R. Jenq, J. Wargo, F. McAllister, *Cell* **2019**, 178, 795; c) T. Murakami, Y. Hiroshima, R. Matsuyama, Y. Homma, R. M. Hoffman, I. Endo, *Ann. Gastroent. Surg.* **2019**, 3, 130.
- [2] a) P. P. Adisheshaiah, R. M. Crist, S. S. Hook, S. E. McNeil, *Nat. Rev. Clin. Oncol.* **2016**, 13, 750; b) Q. Zhou, S. Shao, J. Wang, C. Xu, J. Xiang, Y. Piao, Z. Zhou, Q. Yu, J. Tang, X. Liu, Z. Gan, R. Mo, Z. Gu, Y. Shen, *Nat. Nanotechnol.* **2019**, 14, 799.
- [3] M. Amrutkar, I. P. Gladhaug, *Cancers* **2017**, 9, 157.
- [4] a) M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, R. Langer, *Nat. Rev. Drug Discov.* **2021**, 20, 101; b) Y. Wang, Z. Zhang, C. Zheng, X. Zhao, Y. Zheng, Q. Liu, Y. Liu, L. Shi, *Small* **2021**, 17, e2100578.
- [5] a) Z. Zhang, H. Wang, T. Tan, J. Li, Z. Wang, Y. Li, *Adv. Funct. Mater.* **2018**, 28, 40; b) X. Pan, P. Li, L. Bai, J. Ma, S. Li, F. Zhang, S. Liu, Q. Wu, H. Shen, H. Liu, *Small* **2020**, 16, e2000809; c) Y. He, L. Lei, J. Cao, X. Yang, S. Cai, F. Tong, D. Huang, H. Mei, K. Luo, H. Gao, B. He, N. A. Peppas, *Sci. Adv.* **2021**, 7, eaba0776; d) J. Chen, J. Ding, Y. Wang, J. Cheng, S. Ji, X. Zhuang, X. Chen, *Adv. Mater.* **2017**, 29, 1701170; e) H. Han, Y. Hou, X. Chen, P. Zhang, M. Kang, Q. Jin, J. Ji, M. Gao, *J. Am. Chem. Soc.* **2020**, 142, 4944; f) Q. Sun, Y. Zhu, J. Du, *Biomed. Mater.* **2021**, 16, 042010.
- [6] a) X. He, X. Chen, L. Liu, Y. Zhang, Y. Lu, Y. Zhang, Q. Chen, C. Ruan, Q. Guo, C. Li, T. Sun, C. Jiang, *Adv. Sci.* **2018**, 5, 1701070; b) Y. Wang, D. Huang, X. Wang, F. Yang, H. Shen, D. Wu,

This article is protected by copyright. All rights reserved.

- Biomater. Sci.* **2019**, *7*, 3238; c) J. Liu, C. Chen, T. Wei, O. Gayet, C. Loncle, L. Borge, N. Dusetti, X. Ma, D. Marson, E. Laurini, S. Pricl, Z. Gu, J. Iovanna, L. Peng, X. Liang, *Exploration* **2021**, *1*, 21; d) S. Zhang, S. Zhou, H. Liu, M. Xing, B. Ding, B. Li, *Adv. Funct. Mater.* **2020**, *30*, 2002434.
- [7] a) G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, S. Sarkar, *Cancers* **2014**, *6*, 1769; b) B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang, B. Baradaran, *Adv. harm.Bull.* **2017**, *7*, 339; c) H. Zahreddine, K. L. Borden, *Front.Pharmacol.* **2013**, *4*, 28.
- [8] L. T. Geller, M. Barzily-Rokni, T. Danino, O. H. Jonas, N. Shental, D. Nejman, N. Gavert, Y. Zwang, Z. A. Cooper, K. Shee, C. A. Thaiss, A. Reuben, J. Livny, R. Avraham, D. T. Frederick, M. Ligorio, K. Chatman, S. E. Johnston, C. M. Mosher, A. Brandis, G. Fuks, C. Gurbatri, V. Gopalakrishnan, M. Kim, M. W. Hurd, M. Katz, J. Fleming, A. Maitra, D. A. Smith, M. Skalak, J. Bu, M. Michaud, S. A. Trauger, I. Barshack, T. Golan, J. Sandbank, K. T. Flaherty, A. Mandinova, W. S. Garrett, S. P. Thayer, C. R. Ferrone, C. Huttenhower, S. N. Bhatia, D. Gevers, J. A. Wargo, T. R. Golub, R. Straussman, *Science* **2017**, *357*, 1156.
- [9] C. Jobin, *Nature* **2017**, *550*, 337;
- [10] X. Zhang, X. Chen, Y. Guo, G. Gao, D. Wang, Y. Wu, J. Liu, G. Liang, Y. Zhao, F. G. Wu, *Angew. Chem. Intd. Engl.* **2021**, *60*, 14013.
- [11] a) D. Nejman, I. Livyatan, G. Fuks, N. Gavert, Y. Zwang, L. T. Geller, A. Rotter-Maskowitz, R. Weiser, G. Mallel, E. Gigi, A. Meltser, G. M. Douglas, I. Kamer, V. Gopalakrishnan, T. Dadosh, S. Levin-Zaidman, S. Avnet, T. Atlan, Z. A. Cooper, R. Arora, A. P. Cogdill, M. A. W. Khan, G. Ologun, Y. Bussi, A. Weinberger, M. Lotan-Pompan, O. Golani, G. Perry, M. Rokah, K. Bahar-Shany, E. A. Rozeman, C. U. Blank, A. Ronai, R. Shaoul, A. Amit, T. Dorfman, R. Kremer, Z. R. Cohen, S. Harnof, T. Siegal, E. Yehuda-Shnaidman, E. N. Gal-Yam, H. Shapira, N. Baldini, M. G. I. Langille, A.

- Ben-Nun, B. Kaufman, A. Nissan, T. Golan, M. Dadiani, K. Levanon, J. Bar, S. Yust-Katz, I. Barshack, D. S. Peeper, D. J. Raz, E. Segal, J. A. Wargo, J. Sandbank, N. Shental, R. Straussman, *Science* **2020**, 368, 973. b) A. Fu, B. Yao, T. Dong, Y. Chen, J. Yao, Y. Liu, H. Li, H. Bai, X. Liu, Y. Zhang, C. Wang, Y. Guo, N. Li, S. Cai, *Cell* **2022**, 185, 1356.
- [12] W. Feng, G. Li, X. Kang, R. Wang, F. Liu, D. Zhao, H. Li, F. Bu, Y. Yu, T. F. Moriarty, X. Wang, *Adv. Mater.* 2109789.
- [13] P. P. Kalelkar, M. Riddick, A. J. Garcia, *Nat. Rev. Mater.* **2021**, 7, 39.
- [14] a) M. Zhou, Y. X. Qian, J. Y. Xie, W. J. Zhang, W. N. Jiang, X. M. Xiao, S. Chen, C. Z. Dai, Z. H. Cong, Z. M. Ji, N. Shao, L. Q. Liu, Y. Q. Wu, R. H. Liu, *Angew. Chem. Int. Ed.* **2020**, 59, 6412; b) X. Ding, C. Yang, W. Moreira, P. Y. Yuan, B. Periaswamy, P. F. de Sessions, H. M. Zhao, J. R. Tan, A. Lee, K. X. Ong, N. Park, Z. C. Liang, J. L. Hedrick, Y. Y. Yang, *Adv. Sci.* **2020**, 7, 2001374. c) J. Sun, M. Li, M. Lin, B. Zhang, X. Chen, *Adv. Mater.* 2021, 33, 2104402.
- [15] H. Han, Y. Hou, X. Chen, P. Zhang, M. Kang, Q. Jin, J. Ji, M. Gao, *J. Am. Chem. Soc.* **2020**, 142, 4944.
- [16] Y. Wang, Y. Jiang, D. Wei, P. Singh, Y. Yu, T. Lee, L. Zhang, H. K. Mandl, A. S. Piotrowski-Daspit, X. Chen, F. Li, X. Li, Y. Cheng, A. Josowitz, F. Yang, Y. Zhao, F. Wang, Z. Zhao, A. Huttner, R. S. Bindra, H. Xiao, W. Mark Saltzman, *Nat. Biomed. Eng.* **2021**, 5, 1048.
- [17] a) M. Ye, Y. Zhao, Y. Wang, M. Zhao, N. Yodsanit, R. Xie, D. Andes, S. Gong, *Adv. Mater.* **2021**, 33, e2006772; b) H. Han, J. Zhu, D. Q. Wu, F. X. Li, X. L. Wang, J. Y. Yu, X. H. Qin, *Adv. Funct. Mater.* **2019**, 29, 1806594.

- [18] a) F. Wu, J. Xu, R. Yan, B. Hu, G. Li, M. Jin, X. Jiang, J. Li, P. Tang, J. Zhu, *Biomed. Mater.* **2020**, 15, 045016; b) R. Wu, M. Song, D. Sui, S. Duan, F.-J. Xu, *J. Mater. Chem. B* **2022**, 10, 2471.
- [19] A. Chen, A. Karanastasis, K. R. Casey, M. Necelis, B. R. Carone, G. A. Caputo, E. F. Palermo, *ACS Appl. Mater. Inter.* **2020**, 12, 21270.
- [20] Y. Wu, W. Jiang, Z. Cong, K. Chen, Y. She, C. Zhong, W. Zhang, M. Chen, M. Zhou, N. Shao, *J. Med. Chem.* **2022**, 65, 10, 7296.
- [21] a) A. C. Hortelão, T. Patiño, A. Perez-Jiménez, À. Blanco, S. Sánchez, *Adv. Funct. Mater.* **2018**, 28, 1705086; b) Y. K. Sung, S. W. Kim, *Biomater. Res.* **2020**, 24, 1.
- [22] a) Y. Guo, Y. Xu, Q. Bao, C. Shen, D. Ni, P. Hu, J. Shi, *ACS nano* 2021, 15, 16286; b) D. Yang, W. Chen, J. Hu, *J Phys. Chem. B* **2014**, 118, 12311.
- [23] A. Tsiasioti, I. Iakovidou, C. K. Zacharis, P. D. Tzanavaras, *Spectrochim Acta A Mol Biomol. Spectrosc.* **2020**, 229, 117963.
- [24] X. Meng, J. Zhang, Z. Sun, L. Zhou, G. Deng, S. Li, W. Li, P. Gong, L. Cai, *Theranostics* 2018, **8**, 6025.
- [25] K. Zhang, Y. Du, Z. Si, Y. Liu, M. E. Turvey, C. Raju, D. Keogh, L. Ruan, S. L. Jothy, S. Reghu, K. Marimuthu, P. P. De, O. T. Ng, J. R. Mediavilla, B. N. Kreiswirth, Y. R. Chi, J. Ren, K. C. Tam, X. W. Liu, H. Duan, Y. Zhu, Y. Mu, P. T. Hammond, G. C. Bazan, K. Pethe, M. B. Chan-Park, *Nat. Commun.* **2019**, 10, 4792.
- [26] X. Li, H. Bai, Y. Yang, J. Yoon, S. Wang, X. Zhang, *Adv. Mater.* 2019, 31, 1805092.


- [27] a) M. Li, J. Sun, W. Zhang, Y. Zhao, S. Zhang, S. Zhang, *Carbohydr. Polym.* **2021**, 251, 117103. b) X. Kang, Y. Wang, Z. Chen, Y. Wu, H. Chen, X. Yang, C. Yu, *Chem. Commun.* **2020**, 56, 11271; c) X. Kang, Y. Yu, Z. Chen, Y. Wu, D. Wei, Y. Zhao, F. Wang, H. Xiao, *J. Mater. Chem. B* **2019**, 7, 3346.
- [28] a) F. Sun, Q. Zhu, T. Li, M. Saeed, Z. Xu, F. Zhong, R. Song, M. Huai, M. Zheng, C. Xie, L. Xu, H. Yu, *Adv. Sci.* **2021**, 8, 2002746; b) Q. Zhang, G. Kuang, S. He, H. Lu, Y. Cheng, D. Zhou, Y. Huang, *Nano Lett.* **2020**, 20, 3039; c) K. Y. Choi, H. S. Han, E. S. Lee, J. M. Shin, B. D. Almquist, D. S. Lee, J. H. Park, *Adv. Mater.* **2019**, 31, e1803549.
- [29] a) F. Wang, W. Sun, L. Li, L. Li, Y. Liu, Z. R. Zhang, Y. Huang, *ACS Appl. Mater. Inter.* **2017**, 9, 27563; b) J. Ma, P. Li, W. Wang, S. Wang, X. Pan, F. Zhang, S. Li, S. Liu, H. Wang, G. Gao, B. Xu, Q. Yuan, H. Shen, H. Liu, *ACS Nano* **2018**, 12, 9022.
- [30] J. Stritzker, S. Weibel, P. J. Hill, T. A. Oelschlaeger, W. Goebel, A. A. Szalay, *Int. J. Med. Microbiol.* **2007**, 297, 151.
- [31] a) X. Huang, J. Pan, F. Xu, B. Shao, Y. Wang, X. Guo, S. Zhou, *Adv. Sci.* **2021**, 8, 2003572; b) W. Song, K. Tiruthani, Y. Wang, L. Shen, M. Hu, O. Dorosheva, K. Qiu, K. A. Kinghorn, R. Liu, L. Huang, *Adv. Mater.* **2018**, 30, e1805007.
- [32] a) M. Chang, Z. Hou, M. Wang, C. Li, J. Lin, *Adv. Mater.* **2021**, 33, 2004788; b) Y. Jiang, J. Huang, C. Xu, K. Pu, *Nat. Commun.* **2021**, 12, 1.

### The table of contents entry

Dual-cascade responsive nanoparticles, consisting of a hyaluronic acid shell and a core assembled by an antibacterial polymer, are proposed. The nanoparticle sequentially triggers active tumor targeting, deep tumor penetration, efficient killing of intratumoral bacteria and controlled drug-release. The nanoparticles augment anticancer efficacy by eliminating tumor-resident intracellular bacteria *via* non-antibiotic therapy.

Xiaoxu Kang, Fanqiang Bu, Wenli Feng, Fang Liu, Xuankun Yang, Haofei Li, Yingjie Yu, Guofeng Li, Haihua Xiao, and Xing Wang\*

**Title: Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bacteria**



This article is protected by copyright. All rights reserved.